If you need more lookups,
subscriptions start at $34 USD/month.
Eric Easom Location
Menlo Park, CA, US
Eric Easom Work
2026 -now Board Member @
2019 -now Director, Board of Directors @ Resilient Biotics, Inc.
2018 -now Member Board Of Directors @ Chagas Disease Foundation
2017 -now CEO and Co-Founder @
2010 -2013 Chair Board of Directors @ Infectious Disease Research Institute
2009 -2017 Vice President, Neglected Diseases @
2007 -2009 Sr. Director, Business Development and Marketing @ InteKrin Therapeutics, Inc.
2007 -2014 Member Board of Directors @ Infectious Disease Research Institute
2006 -2007 Director of Marketing @
2005 -2006 Director, Pharmaceutical Division @
2003 -2005 Founder and CEO @ Hope Pharmaceuicals
1990 -2003 US Brand Manager, Endcrine Business Unit and Humatrope @ Eli Lilly & Co.
1997 -2000 Corporate Business Development @ Eli Lilly & Co.
1995 -1997 Finance @ Eli Lilly & Co.
1990 -1994 Engineer, Manufacturing @ Eli Lilly & Co.
Eric Easom Education
Indiana University - Kelley School of Business
MBA (Marketing and Finance)
1995-1997
University of Louisville
Masters (Electrical Engineering)
1989-1990
University of Louisville
BS (Electrical Engineering)
1985-1989
Eric Easom Skills
Infectious Disease R&D
Biotech R&D Leadership
Non-Dilutive Fundraising
Biotechnology
Biochemistry
Business Development
Biotech BOD
Eric Easom Summary
Eric Easom, based in Menlo Park, CA, US, is currently a CEO and Co-Founder at AN2 Therapeutics, Inc.. Eric Easom brings experience from previous roles at Drugs for Neglected Diseases initiative (DNDi), Resilient Biotics, Inc., Chagas Disease Foundation and Infectious Disease Research Institute. Eric Easom holds a 1995 - 1997 MBA in Marketing and Finance @ Indiana University - Kelley School of Business. With a robust skill set that includes Infectious Disease R&D, Biotech R&D Leadership, Non-Dilutive Fundraising, Biotechnology, Biochemistry and more. Eric Easom has 2 emails and 3 mobile phone numbers on RocketReach.
Looking for a different Eric Easom?
Find contact details for 700 million professionals.